ANALYSIS OF 6-MERCAPTOPURINE AND 6-METHYLMERCAPTOPURINE IN DRIED BLOOD SPOTS USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY AND ITS APPLICATION IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

Authors

  • Supandi Supandi Department of Pharmacy, Faculty of Pharmacy, Universitas Indonesia, Depok Campus 16424, Indonesia http://orcid.org/0000-0002-0063-2548
  • Yahdiana Harahap Department of Pharmacy, Faculty of Pharmacy, Universitas Indonesia, Depok Campus 16424, Indonesia
  • Harmita Harmita Department of Pharmacy, Faculty of Pharmacy, Universitas Indonesia, Depok Campus 16424, Indonesia
  • Rizka Andalusia Department of Research and Development, Dharmais Cancer Hospital, Jakarta 11420, Indonesia.
  • Marlina Ika Department of Pharmacy, Faculty of Pharmacy, Universitas Indonesia, Depok Campus 16424, Indonesia

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i9.19790

Keywords:

6-mercaptopurine, 6-methylmercaptopurine, Dried blood spots, Acute lymphoblastic leukemia

Abstract

 

 Objective: To analyze and validate 6-mercaptopurine (6-MP) and 6-methylmercaptopurine (6-MMP) in dried blood spots (DBS) using liquid chromatography-tandem mass spectrometry (LC/MS-MS).

Methods: Bio-sampling dried blood spot with DBS-CAMAG® paper diameter of 8 mm and extracted with acetonitrile-methanol (1:3) containing internal standard 5-fluorouracil (5-FU). Separation was performed with C18 column Acquity® 1.7 μm (2.1 mm × 100 mm), with a mobile phase mixture of 0.1% formic acid in water 0.1% formic acid in acetonitrile with gradient elution and flow rate 0.2 ml/min. Mass detection was Waters Xevo TQD with positive electrospray ionization (ESI) for 6-MP, 6-MMP and negative ESI for 5-FU in multiple reaction monitoring modes. The ions of 6-MP was detected at m/z 153.09->119.09, 6-MMP at m/z 167.17->126.03, and 5-FU at m/z 129.15->42.05.

Results: This method fulfill the requirements of selectivity, linearity, lower limit of quantification, accuracy, precision, carry-over, matrix effects, and stability which refers to the european medicines agency (EMEA) guidelines. The linearity of 0.99 was 26-1000 ng/mL for 6-MP and 6-MMP, respectively. The validated method was applied to two childhood ALL maintenance phase. Retrieved 6-MP levels of 10.37 pmol/8×108 erythrocytes, respectively. The levels of 6-MMP gained 16.59 pmol/8×108 erythrocytes, respectively.

Conclusion: The developed LC/MS-MS method is valid to analysis 6-MP and 6-MMP in DBS simultaneous in vitro according to EMEA guidelines. The method was successfully applied to authentic capillary blood samples from two childhood patients with ALL in the maintenance phase.

Downloads

Download data is not yet available.

References

Hawwa AF, Millership JS, Collier PS, McElnay JC. Development and validation of an HPLC method for the rapid and simultaneous determination of 6-mercaptopurine and four of its metabolites in plasma and red blood cells. J Pharm Biomed Anal 2009;49(2):401-9.

Tijare LK, Ranggari NT, Mahajan UN. A review on bioanalytical method development and validation. Asian J Pharm Clin Res 2016;9 Suppl 1:6-10.

Spooner N, Lad R, Barfield M. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: Considerations for the validation of a quantitative bioanalytical method. Anal Chem 2009;81(7):1557-63.

Sharma A, Jaiswal S, Shukla M, Lal J. Dried blood spots: Concepts, present status, and future perspectives in bioanalysis. Drug Test Anal 2014;6(5):399-414.

Déglon J, Thomas A, Mangin P, Staub C. Direct analysis of dried blood spots coupled with mass spectrometry: Concepts and biomedical applications. Anal Bioanal Chem 2012;402(8):2485-98. 6. Evans C, Arnold M, Bryan P, Duggan J, James CA, Li W, et al. Implementing dried blood spot sampling for clinical pharmacokinetic determinations: Considerations from the IQ consortium microsampling working group. AAPS J 2015;17:292-300.

De Kesel PM, Sadones N, Capiau S, Lambert WE, Stove CP. Hemato-critical issues in quantitative analysis of dried blood spots: Challenges and solutions. Bioanalysis 2013;5(16):2023-41.

Capiau S, Stove VV, Lambert WE, Stove CP. Prediction of the hematocrit of dried blood spots via potassium measurement on a routine clinical chemistry analyzer. Anal Chem 2013;85(1):404-10.

Jakir SK, Rahul SS, Ritu MG. A rapid, sensitive and validated ultra performance liquid chromatography and tandem mass spectrometry method for determination of paromomycin in mice plasma: Aplication to pharmacokinetic study. Int J Pharm Pharm Sci 2017;9(5):86-90.

Kirchherr H, Shipkova M, von Ahsen N. Improved method for therapeutic drug monitoring of 6-thioguanine nucleotides and 6-methylmercaptopurine in whole-blood by LC/MSMS using isotope-labeled internal standards. Ther Drug Monit 2013;35(3):313-21.

European Medicines Agency (EMEA). Committee for Medicinal Products for Human Use (CHMP): Guideline on Bioanalytical Method Validation. London: European Medicines Agency; 2011.

Jager NG, Rosing H, Schellens JH, Beijnen JH. Procedures and practices for the validation of bioanalytical methods using dried blood spots: A review. Bioanalysis 2014;6(18):2481-514.

Narottam P, Avanapu SR, Pigilli R. New method development and validation for the determination of febuxostat in human plasma by liquid chromatography-mass spectrometry. Int J Pharm Pharm Sci 2016;8(9):61-70.

Wael AA, Eyad MM, Israa HA, Tawfiq AA. Liquorice beverage effect on the pharmacokinetic parameters of atorvastatin, simvastatin, and lovastatin by liquid chromatography-mass spectroscopy/mass spectroscopy. Asian J Pharm Clin Res 2016;9:2174-9.

Published

01-09-2017

How to Cite

Supandi, S., Y. Harahap, H. Harmita, R. Andalusia, and M. Ika. “ANALYSIS OF 6-MERCAPTOPURINE AND 6-METHYLMERCAPTOPURINE IN DRIED BLOOD SPOTS USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY AND ITS APPLICATION IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 10, no. 9, Sept. 2017, pp. 120-5, doi:10.22159/ajpcr.2017.v10i9.19790.

Issue

Section

Original Article(s)